| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 146, Issue 9 3227-3234, Copyright © 1991 by American Association of Immunologists
ARTICLES |
AL Asher, JJ Mule, A Kasid, NP Restifo, JC Salo, CM Reichert, G Jaffe, B Fendly, M Kriegler and SA Rosenberg
Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Studies of the anti-tumor activity of TNF-alpha in vivo have been hampered by the need to administer systemically toxic doses of the cytokine to obtain a curative response. To facilitate studies of the effect of high local concentrations of TNF-alpha on tumor growth and host immunity, a newly induced murine sarcoma was transduced with the gene for human TNF-alpha and the biologic characteristics of these cells were examined. We identified high and low TNF-producing tumor clones which exhibited stable TNF secretion over time. Significant amounts of membrane associated TNF were found in a high-TNF producing clone as well. No difference in the in vitro growth rates between TNF- producing and nonproducing cell lines was observed. In contrast, in vivo studies demonstrate that although unmodified parental tumor cells grew progressively when implanted s.c. in animals, tumor cells transduced with the TNF gene were found to regress in a significant number of animals after an initial phase of growth. This effect correlated with the amount of TNF produced and could be blocked with a specific anti-TNF antibody. Regressions of TNF-producing cells occurred in the absence of any demonstrable toxicity in the animals bearing these tumors. TNF-producing tumor cells could function in a paracrine fashion by inhibiting the growth of unmodified, parental tumor cells implanted at the same site. The ability of tumor cells to regress was abrogated by in vivo depletion of CD4+ or CD8+ T cell subsets and animals that had experienced regression of TNF-producing tumors rejected subsequent challenges of parental tumor. Our studies thus show that tumor cells elaborating high local concentrations of TNF regress in the absence of toxicity in the host and that this process requires the existence of intact host immunity. Studies of the lymphocytes infiltrating the gene modified tumors and attempts to use TNF gene modified tumor infiltrating lymphocytes to deliver high local concentrations of TNF to the tumor site without inducing systemic toxicity are underway.
This article has been cited by other articles:
|
|
 |
|
  Y. Lu, W. Yang, C. Qin, L. Zhang, J. Deng, S. Liu, and Z. Qin Responsiveness of Stromal Fibroblasts to IFN-{gamma} Blocks Tumor Growth via Angiostasis J. Immunol., November 15, 2009; 183(10): 6413 - 6421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. Wu, C. N. Pabin, Z. Qin, T. Blankenstein, M. Philip, J. Dignam, K. Schreiber, and H. Schreiber Long-Term Suppression of Tumor Growth by TNF Requires a Stat1- and IFN Regulatory Factor 1-Dependent IFN-{gamma} Pathway but Not IL-12 or IL-18 J. Immunol., March 1, 2004; 172(5): 3243 - 3251. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Friedlander, C. L. Delaune, J. M. Abadie, M. Toups, J. LaCour, L. Marrero, Q. Zhong, and J. K. Kolls Efficacy of CD40 Ligand Gene Therapy in Malignant Mesothelioma Am. J. Respir. Cell Mol. Biol., September 1, 2003; 29(3): 321 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mann, K. Breuhahn, P. Schirmacher, A. Wilhelmi, C. Beyer, A. Rosenau, S. Özbek, S. Rose-John, and M. Blessing Up- and Down-Regulation of Granulocyte/Macrophage-Colony Stimulating Factor Activity in Murine Skin Increase Susceptibility to Skin Carcinogenesis by Independent Mechanisms Cancer Res., March 1, 2001; 61(5): 2311 - 2319. [Abstract] [Full Text]
|
|
|
|
|
|
F. Bazzoni and E. Regalia Triggering of Antitumor Activity Through Melanoma-specific Transduction of a Constitutively Active Tumor Necrosis Factor (TNF) R1 Chimeric Receptor in the Absence of TNF-{{alpha}} Cancer Res., February 1, 2001; 61(3): 1050 - 1057. [Abstract] [Full Text]
|
|
|
|
|
|
M. R. Graf, R. M. Prins, and R. E. Merchant IL-6 Secretion by a Rat T9 Glioma Clone Induces a Neutrophil-Dependent Antitumor Response with Resultant Cellular, Antiglioma Immunity J. Immunol., January 1, 2001; 166(1): 121 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Ali, C. S. McLean, M. E. G. Boursnell, G. Martin, C. L. Holmes, S. Reeder, C. Entwisle, D. M. Blakeley, J. G. Shields, S. Todryk, et al. Preclinical Evaluation of "Whole" Cell Vaccines for Prophylaxis and Therapy Using a Disabled Infectious Single Cycle-Herpes Simplex Virus Vector to Transduce Cytokine Genes Cancer Res., March 1, 2000; 60(6): 1663 - 1670. [Abstract] [Full Text]
|
|
|
|
|
|
D. R. Surman, M. E. Dudley, W. W. Overwijk, and N. P. Restifo Cutting Edge: CD4+ T Cell Control of CD8+ T Cell Reactivity to a Model Tumor Antigen J. Immunol., January 15, 2000; 164(2): 562 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. de Zoeten, V. Carr-Brendel, D. Markovic, J. Taylor-Papadimitriou, and E. P. Cohen Treatment of Breast Cancer with Fibroblasts Transfected with DNA from Breast Cancer Cells J. Immunol., June 1, 1999; 162(11): 6934 - 6941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tanaka, H. Yoshizawa, Y. Yamaguchi, K. Ito, H. Kagamu, E. Suzuki, F. Gejyo, H. Hamada, and M. Arakawa Successful Adoptive Immunotherapy of Murine Poorly Immunogenic Tumor with Specific Effector Cells Generated from Gene-Modified Tumor-Primed Lymph Node Cells J. Immunol., March 15, 1999; 162(6): 3574 - 3582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. F. Greten and E. M. Jaffee Cancer Vaccines J. Clin. Oncol., March 1, 1999; 17(3): 1047 - 1047. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bowman, M. Grossmann, D. Rill, M. Brown, W.-y. Zhong, B. Alexander, T. Leimig, E. Coustan-Smith, D. Campana, J. Jenkins, et al. IL-2 Adenovector-Transduced Autologous Tumor Cells Induce Antitumor Immune Responses in Patients With Neuroblastoma Blood, September 15, 1998; 92(6): 1941 - 1949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. F. de Zoeten, V. Carr-Brendel, and E. P. Cohen Resistance to Melanoma in Mice Immunized with Semiallogeneic Fibroblasts Transfected with DNA from Mouse Melanoma Cells J. Immunol., March 15, 1998; 160(6): 2915 - 2922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Lanni, S. W. Lowe, E. J. Licitra, J. O. Liu, and T. Jacks p53-independent apoptosis induced by paclitaxel through an indirect mechanism PNAS, September 2, 1997; 94(18): 9679 - 9683. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. L. Maria, C. D. Medina, K. B.N. Hoang, and M. I. Phillips Topical Review: Gene Therapy for Neurologic Disease: Benchtop Discoveries to Bedside Applications. 1. The Bench J Child Neurol, January 1, 1997; 12(1): 1 - 12. [Abstract] [PDF]
|
|
|
|
 |
|
 K. M. Wilson, P. J. Stambrook, W. L. Bi, Z. P. Pavelic, L. Pavelic, and J. L. Gluckman HSV-tk Gene Therapy in Head and Neck Squamous Cell Carcinoma: Enhancement by the Local and Distant Bystander Effect Arch Otolaryngol Head Neck Surg, July 1, 1996; 122(7): 746 - 749. [Abstract] [PDF]
|
|
|
|
|
|
S. E. Strome, J. C. Krauss, M. J. Cameron, K. Forslund, S. Shu, and A. E. Chang Immunobiologic Effects of Cytokine Gene Transfer of the B16-BL6 Melanoma Arch Otolaryngol Head Neck Surg, December 1, 1993; 119(12): 1289 - 1295. [Abstract] [PDF]
|
|
|
|
 |
|
 A. E. Chang, J. D. Geiger, V. K Sondak, and S. Shu Adoptive Cellular Therapy of Malignancy Arch Surg, November 1, 1993; 128(11): 1281 - 1290. [Abstract] [PDF]
|
|
|
|
 |
|
 S. A. Rosenberg Gene Therapy for Cancer JAMA, November 4, 1992; 268(17): 2416 - 2419. [Abstract] [PDF]
|
|
|
|
|
|
J. E. Karp and S. Broder Oncology JAMA, July 15, 1992; 268(3): 391 - 393. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
